Background: Disturbances in sleep architecture, especially reductions in slow-wave sleep (SWS), are symptoms commonly observed in individuals with alcohol use disorders. Recent clinical trials have demonstrated that the anticonvulsant and analgesic drug gabapentin may have therapeutic value in normalizing sleep quality in recovering alcoholics. However, the brain mechanisms underlying this improvement in sleep following gabapentin treatment remain unknown.
A CCORDING TO THE 2015 National Survey on Drug Use and Health, 15.1 million adults age 18 and older (6.2%), in the United States, had an alcohol use disorder (SAMHSA, 2015) . Alcohol use disorder is defined by a cluster of psychological, behavioral, and physical symptoms, which can include craving, tolerance, use in dangerous situations and despite harmful consequences, as well as the emergence of a withdrawal syndrome on cessation of use (American Psychiatric Association, 2013) .
After acute withdrawal, chronic alcohol users may complain of light, fragmented sleep with a deficit in slow-wave sleep (SWS) that can persist for months and can contribute to relapse (Brower and Perron, 2010; Drummond et al., 1998) . Alcohol-induced sleep disorder (insomnia) is 1 of 8 core criteria in the DSM-5 diagnosis of alcohol withdrawal (American Psychiatric Association, 2013 ) and refers to difficulty initiating or maintaining sleep, or waking earlier than intended and/or nonrestorative or poor quality sleep as reported by the patient (Brower, 2015) . Insomnia symptoms are distressing to the patient and can interfere with daytime functioning. They may occur despite adequate opportunity for sleep (American Psychiatric Association, 2013) and can compromise the efforts of alcohol-dependent patients to initiate and/or maintain sobriety (Conroy et al., 2006) , even in the absence of mood disorders (Clark et al., 1998) .
Current FDA-approved pharmacologic treatments for insomnia include benzodiazepines and nonbenzodiazepine hypnotics, tricyclic antidepressants, therapeutic drugs that target orexin/hypocretin receptors, and off-label use of drugs such as other antidepressants, antihistamines, herbal preparations, and antipsychotics (for guidelines and reviews, see (Coleman et al., 2017; Qaseem et al., 2016; Sateia et al., 2017) . However, some agents such as benzodiazepines and other hypnotics may not be suitable for the treatment of sleep disturbance in alcohol dependence because of their potential for addiction and collateral effects that can include residual sedation, memory and performance impairment, undesired behaviors during sleep, somatic symptoms, and drug interactions (Mark et al., 2009) .
In 1993, gabapentin (GP), which binds the a2d auxiliary subunit of the voltage-gated calcium channels, was approved by the FDA for the treatment of partial seizures, and later was used in the treatment of a variety of disorders associated with sleep disruption including psychiatric disorders, restless legs syndrome, periodic limb movement disorder, headache, neuropathic pain syndromes, and movement disorders (Magnus, 1999) . Gabapentin enhances SWS in patients with primary insomnia (Foldvary-Schaefer et al., 2002) , improves sleep quality by elevating sleep efficiency and decreasing spontaneous arousals (Bazil et al., 2005; Lo et al., 2010) . Additionally, gabapentin has been demonstrated to improve rates of abstinence, measures of mood, sleep, and craving in alcohol-dependent individuals in several clinical trials (Brower, 2015; Brower et al., 2008; Mason et al., 2014) .
Despite the clear importance of sleep disturbance in the clinical course of alcoholism and the maintenance of sobriety, the complex mechanisms that underlie alcohol-induced insomnia and suitable therapeutic approaches to its management remain to be fully developed. The development of animal models of alcohol-induced insomnia allows for the experimental control necessary to study the effects of ethanol (EtOH), independent of many factors that confound human studies, such as psychiatric comorbidity and other substance use. It also allows for the exploration of both the mechanisms underlying alcohol-induced insomnia and for the testing of potential therapeutic targets. Studies from our laboratory, and others, in rats, have demonstrated that chronic high-dose EtOH exposure can produce long-term persistent changes in sleep, similar to what is seen in human alcoholics. For instance, adult rats treated with chronic EtOH show increases in sleep latency, reductions in the mean duration of SWS episodes, and the total amount of time spent in SWS (Criado et al., 2008; Ehlers and Slawecki, 2000; Ehlers et al., 2013; Thakkar et al., 2015) . Despite the development of these animal models, their use to identify mechanisms underlying alcohol-induced insomnia and to identify therapeutic targets has been limited. This study had 2 specific aims. The first aim was to describe the effects of chronic alcohol exposure on acute alcohol withdrawal using measures of sleep and waking electrophysiology in rats. For the sleep recordings, we employed traditional polysomnography. However, for the waking electrophysiology, we used event-related oscillations (EROs). EROs are oscillatory changes within the dynamics of ongoing electroencephalogram (EEG) rhythms that are synchronized or enhanced by a time locked cognitive and/or sensory stimulus (see (Anokhin, 2014; Basar et al., 2000; Klimesch et al., 2007; Roach and Mathalon, 2008) ). EROs have been shown to be sensitive measures of normal (Basar et al., 1999; Schack and Klimesch, 2002 ) and abnormal cognitive functioning, as well as more importantly, specific endophenotypes for alcohol use disorders (Ehlers et al., 2015; Pandey et al., 2012; Rangaswamy and Porjesz, 2014) . Therefore, we sought to use these measures to index the effects of chronic alcohol exposure and withdrawal on waking EEG. Our second aim evaluated the potential of gabapentin to ameliorate the effects of chronic alcohol exposure on sleep and waking EEG. Although gabapentin has been demonstrated to reduce drinking in an animal model of chronic alcohol vapor exposure (Roberto et al., 2008) , its effects on sleep and EROs in this model has not been evaluated. Therefore, we tested the effects of saline and 2 doses of gabapentin on sleep and waking EROs in rats chronically exposed to EtOH vapor and withdrawal.
MATERIALS AND METHODS

Animal Subjects
Forty-eight male Wistar rats were obtained from Charles River (Raleigh, NC) and arrived on postnatal day (PD) 90. Rats were pair-housed in standard plastic cages in a temperature-controlled room with a 12-hour light/dark cycle. All testing was conducted at the onset of the light cycle, which occurred at 8:00 AM. Food and water were available ad libitum. The work described herein adheres to the guidelines stipulated in the NIH Guide for the Care and Use of Laboratory Animals (NIH publication No. 80-23, revised 1996) and was reviewed and approved by The Scripps Research Institute's Animal Care and Use Committee.
Surgical Procedure
Surgical and electrophysiological recording procedures performed in this study have been previously described (Ehlers and Slawecki, 2000; Ehlers et al., 2013) . Rats (PD 112 to 141) were surgically implanted with screw electrodes in the skull overlying the frontal cortex (AP: 1.5 mm, ML: AE3.0 mm, FR1) and parietal cortex (AP: À4.5 mm, ML: AE4.5 mm) with a corresponding reference electrode posterior to lambda overlying the cerebellum. Surgical coordinates were obtained from the Paxinos and Watson atlas (Paxinos and Watson, 1986 ). An electromyography (EMG) wire electrode was inserted into the rats' neck muscle. EEG and EMG electrodes were connected to a multipin PlasticsOne Ò connector (PlasticsOne, Inc., Roanoke, VA), and the assembly was anchored to the skull with dental acrylic and anchor screws. Rats were given at least 2 weeks of recovery before EEG recording.
EtOH Vapor Exposure
EtOH vapor exposure has been shown to reliably allow for the titration of blood EtOH concentrations (BECs) that are sufficient for inducing physical EtOH dependence. The EtOH vapor inhalation procedure and the chambers used in this study were previously described (Slawecki, 2002) . EtOH vapor chambers were calibrated to produce high to moderate BECs between 175 and 225 mg/dL. In brief, rats (n = 48) were randomly divided into 2 groups each (EtOH group, n = 24; control group, n = 24). After the baseline recordings, EtOH rats were housed in sealed chambers, infused with vaporized 95% EtOH from 8 PM. to 10 AM. For the remaining 10 hours of the day, EtOH vapor was not infused into the chambers. Rats were exposed to this vapor cycle for 8 weeks (PD 173 to 228). Blood samples were collected from the tip of the tail every 3 to 4 days during the 8-week exposure period to assess BECs (average for 8 weeks, 128.2 AE 17.4). Control animals were handled identically to EtOH rats. BECs were determined using the Analox microstatAM1 (Analox Instr. Ltd., Lunenberg, MA). Following the 8-week exposure, EtOH animals were transferred to standard polycarbonate cages for the duration of the experiment. Figure 1 shows graphical representation of the timing of the experimental procedure (Fig. 1A) , the animals' body weights, and the average BECs for the EtOH rats (Fig. 1B) .
Electrophysiological Recordings
After recovery from surgery, rats were habituated to the EEG testing chambers prior to the electrophysiological testing. For waking EROs, animals were placed in individual polycarbonate chambers within a sound and electrically shielded recording chamber. Rats were unrestrained but were spatially restricted. Rats were first presented with auditory stimuli through a small speaker centered approximately 70 cm above the rat's head. Auditory stimuli and EROs were elicited using an oddball plus "noise" paradigm described previously (Ehlers et al., 2012 (Ehlers et al., , 2014 . Each auditory ERO session consisted of 312 trials that lasted approximately 10 minutes and each trial presented 1 of 3 randomly generated tones: standard tone (84% probability, 75db, 1,000 Hz), rare tone (10% probability, 85db, 2,000 Hz), or startle tone (6% probability, 100db, white noise). Individual trials were 1,000 ms in duration (200 ms prestimulus + 800 ms poststimulus), and the interval between tones varied from 750 to 1,500 ms.
A 5-hour EEG sleep recording occurred about 5 minutes after the conclusion of the ERO session. All rats were determined to be awake at the start of each EEG session. Signals were transferred to a PC and digitized at a rate of 256 Hz. The EEG amplifier input range corresponding to the full range of the 12-bit analog-to-digital converter was about AE 250 microvolts. Periodic calibration results were used to scale the digitized EEG to microvolts.
Rats were given a baseline electrophysiology session that consisted of an oddball auditory event-related potential (ERP) test during waking, to generate EROs followed by a 5-hour EEG sleep recording prior to EtOH exposure (PD 145 to 169). A second ERO, and 5-hour sleep recording session was conducted 24 hours after withdrawal from the vapor chambers (PD 229 to 238). Approximately 1 month after acute alcohol withdrawal, all rats had 3 additional recording sessions (ERO, and 5-hours sleep) following the administration of: saline, low (30 mg/kg), or high (120 mg/kg) dose gabapentin (PD 271 to 300) (described below) prior to the recordings. For all sessions, the recordings began at "lights on" at 08:00.
Acute Gabapentin and Saline Administration
All rats received their saline (intraperitoneally) as the first of the 3 injections that were followed by recording sessions. Following the injection, they were placed in the electrophysiological recording chamber and the test session began approximately 15 minutes postinjection. Two additional sessions were conducted with a randomized administration of 2 doses of gabapentin (Tokyo Chemical Industry Co., Ltd, Tokyo, Japan): low dose (30 mg/kg) or high dose (120 mg/kg). These doses were selected as they corresponded to the doses reported previously to produce reductions in drinking as well as to reverse the anxiogenic effects of EtOH abstinence in EtOH vapor exposed rats (Roberto et al., 2008) . At least a week was given between doses to avoid carryover effects from the drug. The gabapentin concentrations were prepared fresh for each day of testing for groups containing 3 to 6 rats each, and the saline doses were given in equal frequency and at equivalent volumes to the gabapentin doses.
Sleep Analysis
SWS was visually identified as synchronized slow-wave activity (1 to 4 Hz) during the 5-hour EEG recording session that included baseline, 24-hour withdrawal after EtOH vapor or control exposure, saline injection control, gapapentin 30 mg/kg, and gabapentin 120 mg/kg. Increases in EEG power of at least twice the amplitude of waking baseline EEG power lasting longer than 8 seconds were counted as episodes of SWS. Sleep patterns were analyzed by (1) determining the onset latency of the first episode of SWS, (2) calculating the mean duration of all episodes of SWS, and (3) counting the total number of instances of SWS. The onset of the first SWS episode was identified from the raw EEG as the first transition from low-amplitude high-frequency EEG to SWS (high-amplitude low-frequency EEG) and lasting at least 8 seconds.
Waking EEG Analyses of ERO Energy
Data from single trials generated by the ERP stimuli were entered into a time-frequency analyses algorithm, S-transform, a generalization of the Gabor transform (Stockwell et al., 1996) . The S-transform mathematically resembles the continuous wavelet transform, but it uses Gaussian windows which do not meet a requirement of wavelet analysis, and it includes a "phase correction" that is not part of wavelet analysis. The actual use of the S-transform was simplified by performing first a forward Fourier transform of the time series. Then, for each frequency of the Fourier transform, the results of multiplication were summed by a set of Fourier transforms of Gaussian windows of varying width. Finally, for each of these sums, the inverse of the Fourier transform was taken. The S-transform resulted in a time-frequency representation of the data. The exact code we used is a C language, S-transform subroutine available from the NIMH MEG Core Facility website (http://kurage.nimh.nih.gov/meglab/). This code is specifically for use with real time series, so it sets the input imaginary values, required by the S-transform, to zero, and it always uses the Hilbert transform so that each of the complex output time series is an analytic signal.
To reduce anomalies in the S-transform output at the beginning and the end of the output time series, we used a Hanning window over the initial and final 100 ms of the input time series. The output of the transform for each stimulus and electrode site was calculated by averaging the individual trials containing the time-frequency energy distributions. To quantify S-transform magnitudes, a region of interest (ROI) is defined by specifying the band frequencies and time interval dimensions of the rectangular ROI. The time-frequency points saved from each S-transformation are from 200 ms before to 800 ms after the onset of the stimulus and from 1 through 50 Hz at intervals of 0.5 Hz. Energy is the square of the magnitude of the S-transform output in a time-frequency ROI. The S-transform output for a time-frequency ROI, for a specific EEG lead, is proportional to the input voltage of the lead over the time-frequency interval. The S-transform magnitude squared for a time-frequency interval is therefore proportional to volts squared. These analyses are similar to what has been previously described (Thatcher, 2012) .
Rectangular ROIs were defined within the time-frequency analysis plane by specifying, for each ROI, a band of frequencies and a time interval relative to the stimulus onset time. Time 0 in these definitions is the onset of the stimulus. The 3 ROIs were delta band, 1 to 4 Hz, 200 to 500 ms, theta band, 4 to 7 Hz, 10 to 400 ms, and beta band, 13 to 30 Hz, 0 to 300 ms. These regions were chosen a priori to coincide with the major EEG frequencies present in the rat and the latency windows of the N1, P3a, and P3b ERP components in the rat reported previously (Ehlers et al., 2014) . Using mean values over trials, the maximum energy values were calculated for each ROI, at each electrode location.
Statistical Analyses
Statistical analyses were performed using SPSS (IBM Corp, Armonk, NY) software to test the 2 research aims. For aim 1, to test the effects of alcohol exposure and withdrawal on sleep and EEG parameters, a 2-way group (EtOH vs. control) 9 time (baseline vs. 24-hour withdrawal) analysis of variance (ANOVA) was used. The variables assessed in the analyses for aim 1 were number of SWS sleep episodes, the onset and duration of the first SWS episode, mean duration of SWS events, and ERO energy in the 3 ROIs to the rare tone in the 2 leads (Fz, Pz). For aim 2, to determine the effect of saline and gabapentin on the sleep and ERO measures, a 2-way group (EtOH vs. control) 9 treatment (saline, 30, 120 mg/kg gabapentin) ANOVA was employed using the same sleep and EEG variables described for aim 1. In both sets of analyses, post hoc analyses were conducted when significant main effects were found. Values are presented as mean AE standard error of the mean (SEM), and significances were considered at p < 0.05. Due to loss of electrode function over time, the number of animals in each group differed depending on the condition.
RESULTS
Effects of Chronic EtOH Exposure and 24 Hours of Withdrawal on Sleep
The first research aim concerned the effects of chronic alcohol exposure and 24 hours of withdrawal on sleep and waking electrophysiology in rats. Significant effects were found in sleep measures when baseline prior to EtOH exposure was compared to 24 hours following withdrawal. Repeated-measures ANOVA revealed a significant main effect of group on acute alcohol withdrawal in the latency to SWS (group: F(1, 40) = 4.0, p = 0.05; interaction, F(1, 40) = 9.5, p = 0.004). As seen in Fig. 2A , post hoc analyses revealed that latency to SWS was reduced in the EtOHexposed group as compared to the control (post hoc: control = 3,457.8 AE 420 seconds vs. EtOH = 1,163.6 AE 473.5 seconds, F(1, 41) = 12.9, p = 0.001). No significant differences were found between the EtOH and control rats in the duration of the first SWS episode (group effect: control = 69.8 AE 16.9 seconds vs. EtOH = 69.5 AE 17.5 seconds, p = 0.9, Fig. 2B ). However, a significant main effect of EtOH withdrawal was found in the mean duration of SWS episodes (time: F(1, 40) = 9.3, p = 0.004) and in the number of SWS episodes (time: F(1, 40) = 5.0, p = 0.03; group, F(1, 40) = 9.4, p = 0.004; group 9 time interaction, F(1, 40) = 10.9, p = 0.002). Post hoc analyses revealed that, in the EtOH-exposed group, the number of SWS episodes was markedly increased (control = 57.5 AE 2.3 vs. EtOH = 79.6 AE 4.2, F(1, 41) = 19.9, p < 0.001, Fig. 2C ), and the mean duration of SWS episodes was reduced (control = 100.2 AE 7.3 seconds vs. EtOH = 81.6 AE 5.5, F(1, 41) = 4.2, p < 0.05, Fig. 2D ).
Effects of Chronic EtOH Exposure and 24 Hours of Withdrawal on EROs Energy
Chronic EtOH exposure and withdrawal also produced effects on ERO energy in the 3 frequency bands (delta, theta, and beta). Repeated-measures ANOVA showed that, compared to their respective baseline, during 24-hour withdrawal, there was a time and time 9 group interaction in ERO energy in the delta frequency band in frontal cortex (time: F(1, 37) = 46.2, p < 0.001; group 9 time interaction: F (1, 37) = 4.7, p < 0.05) and in parietal cortex (time: F(1, 39) = 16.0, p < 0.001; group 9 time interaction: F(1, 39) = 5.3, p < 0.05). In addition, there was a time effect in the theta (time: F(1, 37) = 13.6, p = 0.001), and beta (time: F(1, 37) = 15.9, p < 0.001) frequency bands in frontal cortex and in the beta (time: F(1, 39) = 10.8, p = 0.002) frequency bands in the parietal cortex. Post hoc analyses revealed a significant increase in EROs energy during withdrawal in the delta (control = 152.7 AE 19.2 vs. EtOH = 206.5 AE 18.8, F(1, 40) = 4.0, p = 0.05) and beta (control = 232.6 AE 27.7 vs. EtOH = 333.4 AE 28.4, F(1, 40) = 6.4, p = 0.02) frequency bands in the EtOH-exposed group in the parietal cortex (Fig. 3) . Post hoc analyses did not reveal further differences in ERO energy in any frequency band in frontal cortex.
Effects of Saline and Gabapentin on EtOH-Induced Alterations of Sleep
Our second aim evaluated the potential of gabapentin to ameliorate the effects of chronic alcohol exposure on sleep and waking EEG observed following alcohol withdrawal. A 2-way repeated-measures ANOVA, for group (EtOH vs. control) and treatment (saline, 30, 120 mg/kg), was used. A main effect of treatment was seen in the number of SWS episodes (treatment: F(2, 34) = 4.5; p = 0.03, Fig. 2C ). Post hoc analyses showed that the increase in the number of SWS episodes observed during the acute withdrawal, in the EtOHexposed group, persisted in the saline condition 1 month following withdrawal (control = 39.9 AE 3.7 vs. EtOH = 54.6 AE 5.0, F(1, 36) = 5.0, p = 0.03, Fig. 2C ). Gabapentin was found to reduce the number of SWS episodes so that . Mean values and significant statistics from post hoc ANOVA for (A) latency to SWS, (B) duration of first SWS, (C) number of SWS states, and (D) mean duration of SWS. ANOVA showed that in alcohol withdrawal latency to first SWS decreased (A) while SWS became fragmented with a significant increase in the number of SWS episodes (C) but a significant decrease in the mean duration of each episode (D). Gabapentin caused a dose-dependent decrease in the latency to the first SWS episode (A) and an increase in the duration of the first SWS episodes (B). Additionally, gabapentin ameliorated significant differences between vapor exposed and control animals with a dose-dependent decrease in the number of SWS episodes (C) and an increase in the mean duration SWS episodes (D). * indicates p < 0.05 ethanol effect compared to control. ** indicates p < 0.01 EtOH effect to control. Error bars = SEM. similar levels were seen between the 2 groups at both the 30 mg/kg dose (post hoc: control = 44.9 AE 2.9 vs. EtOH = 49.2 AE 3.1, p = 0.3) and the 120 mg/kg dose (post hoc: control = 37.2 AE 2.7 vs. EtOH = 41.3 AE 2.5, p = 0.3).
Repeated-measures ANOVA also showed a treatment effect for the mean duration of SWS episodes (treatment: F(2, 34) = 102; p < 0.001, Fig. 2D ). The reduction in the mean duration of all of the SWS episodes observed during acute Fig. 3 . Effects of chronic ethanol (EtOH) exposure and withdrawal, and saline and gabapentin on event-related oscillation (ERO) energy. ANOVA showed that during withdrawal chronic EtOH exposure increased ERO energy in delta and beta frequency bands in parietal cortex; gabapentin induced dose-dependent increases in EROs energy in all bands for both brain regions with controls having significantly higher response compared to vapor exposed animals in theta and beta frequency bands in frontal cortex and in theta frequency band in the parietal cortex. * indicates p < 0.05 EtOH effect compared to control. Error bars = SEM.
withdrawal was also found to persist into the saline condition in the EtOH-exposed group (control = 122.4 AE 8.6 seconds vs. EtOH = 82.1 AE 6.7 seconds, F(1, 36) = 14.1, p = 0.001, Fig. 2D ). Gabapentin was found to increase the mean duration of all of the SWS episodes bringing the duration of SWS in the EtOH group to similar levels seen the control group at both 30 mg/kg (post hoc: control = 194.1 AE 15.5 seconds vs. EtOH = 164.8 AE 10.0 seconds, p = 0.1) and 120 mg/kg (post hoc: control = 281.9 AE 22.4 seconds vs. EtOH = 237.7 AE 17.1 seconds, p = 0.1). Repeated-measures ANOVA showed that gabapentin caused a dose-dependent decrease in the latency to the first SWS episode (treatment: F(2, 34) = 40.3; p < 0.001, Fig. 2A ) and an increase in the duration of the first SWS episode (treatment: F(2, 34) = 8.4, p = 0.005, Fig. 2B ) in both groups (control and EtOH-exposed group) with no significance differences between the 2 groups at any dose.
Effects of Saline and Gabapentin on EROs Energy
Our second aim also evaluated whether the response to saline and gabapentin, as indexed by waking ERO energy, differed between the control and EtOH-exposed groups in frontal and parietal cortex. Repeated-measures ANOVA revealed an effect of treatment (saline, gabapentin 30, 120 mg/kg) on ERO energy in delta frequency band in frontal cortex (treatment: F(2, 34) = 7.5, p = 0.001) and parietal cortex (treatment: F(2, 35) = 10.9, p < 0.001); however, post hoc analyses revealed no significant differences between the control and EtOH-exposed groups in either cortices (Fig. 3) . In addition, repeated-measures ANOVA revealed group, treatment, and group 9 treatment interactions in ERO energy in theta (group: F(1, 35) = 5.8, p = 0.02; treatment: F(2, 34) = 10.9, p = 0.001; interaction, F(2, 70) = 6.1, p = 0.01) frequency band, and dose with dose 9 group interaction in beta (treatment: F(2, 34) = 9.5, p = 0.001; group 9 treatment interaction: F(2, 70) = 6.4, p = 0.008) frequency band in the frontal cortex. Post hoc ANOVA revealed a significant increase in ERO energy in the control rats, but not in the EtOH rats, in the theta frequency band after injection of gabapentin 30 mg/kg (control = 912.4 AE 220.1 vs. EtOH = 406.0 AE 36.5, F(1, 36) = 5.4, p = 0.026) and further increases in ERO energy in the theta frequencies after injection of gabapentin 120 mg/kg (control = 1,177.7 AE 268.4 vs. EtOH = 505.1 AE 46.6, F(1, 36) = 6.4, p = 0.016) and increases in EROs energy in the beta frequency band after gabapentin 120 mg/kg (control = 969.4 AE 186 vs. EtOH = 511.6 AE 68.6, F(1, 36) = 5.5, p = 0.024).
In the parietal cortex, repeated-measures ANOVA revealed a treatment effect and group 9 treatment interaction in ERO energy in theta (treatment: F(2, 35) = 5.0, p = 0.02; interaction, F(2, 72) = 3.8, p = 0.04) frequency band and a treatment effect in beta frequency band (treatment: F(2, 35) = 5.2, p = 0.01). Post hoc ANOVA revealed a significant increase in ERO energy in the theta frequency band for the control rats, but not for the EtOH rats, following injection of gabapentin 120 mg/kg (control = 905.5 AE 184.3 vs. EtOH 544.5 AE 43.0, F(1, 37) = 4.4, p = 0.04). Post hoc analysis revealed no significant difference between groups on ERO energy in beta frequency band (Fig. 3) .
DISCUSSION
During chronic alcohol exposure, key neurobiological mechanisms underlying the homeostatic regulation of sleep and arousal become dysregulated. This dysregulation results in a protracted alcohol "withdrawal-like state" that includes changes in affective and motivational behaviors as well as changes in sleep (Ehlers and Slawecki, 2000) . We have shown that there is a critical length of time necessary for an animal to be exposed to alcohol vapor in order to induce neuroadaptive changes in both behavior and neurochemistry that persist into protracted withdrawal (Walker et al., 2010) , which is between 6 and 8 weeks of vapor exposure. One of those neuroadaptive changes involves sleep pathology. Here, we show that after chronic alcohol exposure SWS became fragmented during withdrawal as indexed by a significant increase in the number of SWS episodes and significant decrease in the duration of each episode. This finding is particularly important because it correlates with our epidemiological study in human populations where alcohol use disorders are significantly associated with poorer quality of sleep in young adults .
Alcohol withdrawal was also found to influence waking EEG activity as indexed by EROs. Twenty-four hours following withdrawal from the vapor or control chambers, EtOH-exposed rats had significantly increased ERO energy in beta frequency band in the parietal cortex with no other evident changes in any other frequency or region. These studies are also complementary to studies in human subjects where increased beta activity has been reported in many studies in human alcoholics during waking and sleep (see Bauer, 2001; Fein and Allen, 2005; Irwin et al., 2000; Porjesz et al., 2005; Rangaswamy et al., 2002) . EEG beta has been suggested to represent a sign of neural excitability or "disinhibition" when seen in alcoholics (Porjesz et al., 2005) . It has also been demonstrated to be a good endophenotype in genetic studies of families with alcohol use disorders (Meyers et al., 2017; Porjesz et al., 2002) . Taken together, these studies suggest that beta EEG/ERO activity may be an important biomarker that could potentially be used to unravel the mechanisms underlying alcohol use disorder as well as provide a target for therapeutics.
Despite the abundance of data on the importance of alcohol-induced sleep disturbance to the clinical course of alcoholism (Kolla et al., 2014) , there have been few studies that have specifically evaluated therapeutic agents for insomnia in animal models of protracted alcohol withdrawal (Ehlers and Slawecki, 2000; Veatch, 2006) . Recently, gabapentin which binds the a2d-1 and -2 auxiliary subunit (Cole et al., 2005; Dolphin, 2013; Gee et al., 1996) of the voltage-gated calcium channels has been demonstrated to reduce drinking in the alcohol vapor exposure model (Roberto et al., 2008) , although its effect in animal models of sleep physiology and waking EROs has not been previously explored. In the present study, we found that gabapentin administration affected sleep physiology by inducing a dose-dependent decrease in the latency to the first SWS episode, an increase in the duration of SWS episodes concomitant with a decrease in the number of SWS episodes (decreased sleep fragmentation). These effects were opposite to the effects of chronic alcohol exposure where increased sleep fragmentation was seen. Thus, gabapentin has the capability to reverse several of the sleep-disrupting effects of alcohol. Interestingly, gabapentin also had a surprisingly large effect on waking EEG activity, as indexed by ERO energy, which differed depending on a history of chronic alcohol vapor exposure. Gabapentin produced an increase in theta and beta ERO energy; however, those rats with a history of chronic EtOH vapor exposure and withdrawal had a significantly blunted response to gabapentin in ERO energy as compared to the control group. Our findings on the effect of gabapentin on SWS support other studies in rat models (Wodarski et al., 2015) and extrapolate to findings observed in humans (Bazil et al., 2005; Foldvary-Schaefer et al., 2002) supporting its use as a potential therapeutic for sleep disruption associated with alcoholism.
Studies of the effects of gabapentin, which binds the a2d auxiliary subunit of the voltage-gated calcium channels, on waking and sleep EEG may also help reveal how it is involved in sleep and arousal regulation. Cole and colleagues (2005) have shown that several brain regions contain a high density of the a2d subunits of L-type voltage-gated calcium channels, including areas involved in SWS regulation. The median preoptic nuclei and the lateral hypothalamic areas were found to be rich in a2d-2 mRNA-labeled cells. In addition, a2d-1 and a2d-2 mRNAs were found to be highly expressed in the locus coeruleus and the dorsal raphe in the reticular core of the brainstem, whereas moderate levels a2d-1 and a2d-2 mRNAs were found in the pedunculopontine nucleus. These findings are important because all these areas are important in the regulation of sleep-wake transitions and rapid eye movement sleep (Saper and Fuller, 2017) .
There are also data to suggest that alcohol may influence sleep physiology through a mechanism involving these voltage-gated calcium channels. Katsura and colleagues (2006) have shown that sustained EtOH exposure significantly enhances the expression of a2d-1 subunit of L-type voltagegated calcium channels in cortical neurons of mice who were exposed to EtOH vapor. Those observations further support earlier findings where prolonged exposure to EtOH (6 days) was found to increase depolarization-stimulated 45 Ca 2+ uptake in PC12 cells in vitro (Greenberg et al., 1987) and to increase the number of dihydropyridine binding sites located on L-type calcium channels. Taken together, these findings suggest that chronic EtOH exposure can increase the number of voltage-dependent Ca 2+ channels in neural tissues, in the rat. Additionally, showed that chronic treatment with nitrendipine (a calcium channel antagonist) given concurrently with EtOH, prevented symptoms of EtOH withdrawal, and also attenuated the rise in the number of central dihydropyridine binding sites, in mice . Several studies suggest that gabapentin may also act on voltage-gated calcium channels. In animal models of neuropathic pain, it has been shown that the a2d-1 calcium subunit controls neurotransmitter release and that its up-regulation further facilitates excitatory transmission. Overexpression of a2d-1 increases the frequency, but not the amplitude, of miniature excitatory postsynaptic currents in the dorsal horn and that effect has been shown to be reversed by gabapentin administration (Zhou and Luo, 2014) . Therefore, it has been suggested that the a2d-1 subunit of the voltage-gated calcium channels is necessary for the analgesic actions of gabapentin (Zhou and Luo, 2014) . We speculate that chronic EtOH exposure may involve the up-regulation of the a2d subunit influencing activity-dependent calcium signaling cascades leading to the hyperexcitability seen in EtOH withdrawal, and further, that gabapentin could reduce this hyperexcitability by acting on these pathways (Dolphin, 2016) .
Although the exact mechanisms of alcohol-induced sleep disturbance remain unclear, our studies support the hypothesis that chronic EtOH exposure produces changes in sleepwake physiology consistent with a state of neuronal hyperexcitability. We demonstrate that the changes seen in sleep-wake physiology, following chronic EtOH exposure, primarily involve a fragmentation of sleep and an increase in ERO beta frequencies. Gabapentin was found to reverse these effects but also produced a dose-dependent increase in ERO energy in the control group that was significantly larger than the EtOHexposed group in the theta frequency bands. Taken together, these studies suggest that gabapentin can reverse some of the alcohol-induced sleep and EEG deficits but does not eliminate all of the enduring brain effects of EtOH exposure.
